Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Nefrología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer
INTERVENTIONAL
Inicio: 1 de sept de 2006
ID: NCT00338884
Terminado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
INTERVENTIONAL
Inicio: 1 de dic de 2007
ID: NCT00580216
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
INTERVENTIONAL
Inicio: 3 de ene de 2017
ID: NCT03024996
Reclutando
Fase 2
ClinicalTrials.gov
A Phase II Randomised, Double-blind, Parallel-group, Multicentre, International Trial to Investigate the Safety and Efficacy of Vicadrostat and Empagliflozin Administered With Simultaneous vs Staggered Initiation in Participants With Chronic Kidney Disease at Risk of Kidney Disease Progression
INTERVENTIONAL
Inicio: 18 de jul de 2025
ID: NCT06926660
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
INTERVENTIONAL
Inicio: 1 de jun de 2013
ID: NCT01865747
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.
INTERVENTIONAL
Inicio: 1 de nov de 2003
ID: NCT00073307
Completado
ClinicalTrials.gov
Surveillance Registry Of Sirolimus Use In Recipients Of Kidney Allograft From Expanded Criteria Donors (ECD)
OBSERVATIONAL
Inicio: 1 de may de 2008
ID: NCT00697112
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
INTERVENTIONAL
Inicio: 25 de jun de 2021
ID: NCT04629248
Completado
Fase 2
ClinicalTrials.gov
A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial of Multiple Sublingual 5-MeO-DMT Microdoses for Reducing Anxiety and/or Depression in Patients With Mild Cognitive Impairment.
INTERVENTIONAL
Inicio: 15 de dic de 2024
ID: NCT06812221
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents
INTERVENTIONAL
Inicio: 28 de sept de 2016
ID: NCT02879305
Completado
ClinicalTrials.gov
Prevalence of Systemic Inflammation in Patients With Atherosclerotic Cardiovascular Disease and Heart Failure
OBSERVATIONAL
Inicio: 23 de nov de 2023
ID: NCT06122961
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)
INTERVENTIONAL
Inicio: 28 de oct de 2021
ID: NCT05043090
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Severe Renal Impairment Who Have Inadequate Glycemic Control
INTERVENTIONAL
Inicio: 16 de ago de 2017
ID: NCT03242018
Completado
Fase 4
ClinicalTrials.gov
A Randomized, Open Label Study Evaluating the Effect on Renal Function of Intravenous Bonviva Given by Injection or Infusion, Compared With Oral Alendronate, in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
INTERVENTIONAL
Inicio: 1 de jul de 2007
ID: NCT00503113
Completado
ClinicalTrials.gov
An International, Non-randomised, Non-interventional, Multicentre Study to Identify and Characterise Patients With CKD and High Proteinuria for Possible Participation in Future Renal Clinical Studies.
OBSERVATIONAL
Inicio: 31 de jul de 2023
ID: NCT05967806
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)
INTERVENTIONAL
Inicio: 26 de dic de 2023
ID: NCT06099782
Completado
Fase 3
ClinicalTrials.gov
Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
INTERVENTIONAL
Inicio: 26 de may de 2010
ID: NCT01214421
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy for Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors
INTERVENTIONAL
Inicio: 21 de jun de 2019
ID: NCT03873402
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
INTERVENTIONAL
Inicio: 9 de jun de 2017
ID: NCT03142334
Completado
Fase 3
ClinicalTrials.gov
A 28 Week Extension to a 24 Week Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of Vildagliptin (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
INTERVENTIONAL
Inicio: 1 de sept de 2008
ID: NCT00765830
Anterior
1
...
9
10
11
...
434
Siguiente
Filtros